Table 2.
Physician familiarity with breast and/or ovarian cancer preventive intervention options.
| Family Medicine n (%) |
Internist n (%) |
OB/GYN n (%) |
Total n (%) |
|
|---|---|---|---|---|
| Tamoxifen* | ||||
| Familiar | 130 (52.0%) | 153 (61.2%) | 182 (72.8%) | 465 (62.0%) |
| Not as familiar | 120 (48.0%) | 97 (38.8%) | 68 (27.2%) | 285 (38.0%) |
| Raloxifene* | ||||
| Familiar | 103 (41.2%) | 133 (53.2%) | 150 (60.0%) | 386 (51.5%) |
| Not as familiar | 147 (58.8%) | 117 (46.8%) | 100 (40.0%) | 364 (48.5%) |
| Aromatase inhibitors* | ||||
| Familiar | 88 (35.2%) | 128 (51.2%) | 144 (57.6%) | 360 (48.0%) |
| Not as familiar | 162 (64.8%) | 122 (48.8%) | 106 (42.4%) | 390 (52.0%) |
| Prophylactic mastectomy* | ||||
| Familiar | 146 (58.4%) | 161 (64.4%) | 180 (72.0%) | 487 (64.9%) |
| Not as familiar | 104 (41.6%) | 89 (35.6%) | 70 (28.0%) | 263 (35.1%) |
| Oophorectomy* | ||||
| Familiar | 128 (51.2%) | 143 (57.2%) | 230 (92.0%) | 501 (66.8%) |
| Not as familiar | 122 (48.8%) | 107 (42.8%) | 20 (8.0%) | 249 (33.2%) |
| Risk-reducing salpingo-oophorectomy* | ||||
| Familiar | 105 (42.0%) | 119 (47.6%) | 234 (93.6%) | 458 (61.1%) |
| Not as familiar | 145 (58.0%) | 131 (52.4%) | 16 (6.4%) | 292 (38.9%) |
*
Indicates significant difference between provider types (p≤ 0.05)